Presented May 16, 2018 by MI Bioresearch
Hosted by Xtalks
Flow cytometry provides a highly adaptable and quantitative method for investigating both the cellular distribution and intracellular changes that occur in tumors and peripheral lymphoid organs in response to therapy. As clinical successes with cancer immunotherapy accumulate, preclinical immuno-oncology research depends on greater mechanistic understanding of novel therapeutic strategies. MI Bioresearch offers comprehensive flow panels for immune profiling and functional characterization of immune cell activation state.
The objectives of this presentation are three-fold. This presentation will describe advances in flow cytometry-based tools and provide an understanding of how these applications can be used to examine your drug’s mechanism of action.
- Advanced approaches to ex vivo myeloid and lymphoid immunophenotypic analysis. Emphasis will be placed on the challenges presented by the complex nature of tumor-derived cell analysis. The speakers will describe how these challenges have been overcome to delineate myeloid subsets including myeloid-derived suppressor cell, macrophage, and dendritic cell subsets. Furthermore, the speakers will demonstrate techniques that can help interpret the effects that in vivo therapy has on immunosuppression in T cells.
- Demonstration of techniques that analyze cytokine responses in T cells and other lymphoid cells, which have been documented to drive anti-tumor activity within the tumor microenvironment. Using a case study they will illustrate how these applications can help interpret the efficacy of new drugs.
- Ex vivo data discussion that dissects the therapeutic effects on MAPK and JAK/STAT signaling pathways in both the tumor cells and tumor-infiltrating lymphocytes simultaneously.